MCT4-mediated lactate efflux promotes STING-dependent dendritic cell antitumor immunity.
Blocking a tumor cell molecule that suppresses immune responses could enhance immunotherapy effectiveness by activating immune cells more powerfully.
MCT4-mediated lactate efflux from tumor cells activates the STING pathway in dendritic cells, creating a novel metabolic-immune coupling mechanism that promotes antitumor DC immunity; targeting MCT4 represents a new approach to enhancing immunotherapy efficacy. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Mechanistic laboratory study with in vitro and in vivo models (Cell Reports, Nanjing Medical University)
- Category
- novel_therapeutics
- Maturity
- Exploratory
- Journal
- Cell Reports
Why it surfaced
High-impact Cell Reports mechanistic discovery of MCT4-STING-DC axis; novel targetable mechanism relevant to immunotherapy combination strategies; directly addresses tumor metabolic immunosuppression watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.